第三届董事会 2025 年第五次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-070 海南葫芦娃药业集团股份有限公司 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届董事会 2025 年第五次临时会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关规 定，会议合法有效。 （二）会议通知于 2025 年 9 月 25 日以通讯方式发出。 （三）会议于 2025 年 9 月 29 日在海南省海口市秀英区安读一路 30 号公司会议室 以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决方式 出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体监事、高级管理人员列 席会议。 二、董事会会议审议情况 （一）审议通过了《关于取消监事会并修订<公司章程>及其附件的议案》 为进一步促进公司规范运作，建立健全内部治理机制，根据《公司法 ...

Group 1 - ST HuLuWa held its fifth temporary board meeting of the third session on September 29, 2025, in Haikou, Hainan Province, to review proposals regarding the revision and formulation of certain governance systems [1] - For the year 2024, ST HuLuWa's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report date, ST HuLuWa has a market capitalization of 3.5 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yi Bao has intensified, with Nongfu Spring's green bottle launch leading to a significant decline in Yi Bao's market share, dropping nearly 5 percentage points [1]

海南葫芦娃药业集团股份有限公司 关于为全资子公司提供担保的公告 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-069 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | 被担保人名称 本次担保金额 | 3,850 万元 | 广西维威制药有限公司 | | | --- | --- | --- | --- | --- | --- | | 担 保 | 对 | | | | | | 象 | | 实际为其提供的担保余额 | 21,996.34 | 万元（不含本次） | | | | | 是否在前期预计额度内 | 是 □否 | | □不适用：_________ | | | | 本次担保是否有反担保 | □是 否 | | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 29,484.74（不含本次） | | 对外担保总额占上市公司最近一 ...

Group 1 - ST HuLuWa announced that as of the disclosure date, the company and its controlling subsidiaries do not provide guarantees to entities outside the consolidated financial statements, with a total guarantee balance of approximately 295 million yuan, accounting for 42.09% of the company's latest audited net assets, and there are no overdue guarantees [1] - For the year 2024, ST HuLuWa's revenue composition is entirely from the pharmaceutical manufacturing industry, with a 100.0% share [1] - As of the report, ST HuLuWa has a market capitalization of 3.5 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yi Bao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yi Bao, dropping nearly 5 percentage points [1]

Summary of Key Points Core Viewpoint - The recent block trade of Chahua Co., Ltd. indicates significant trading activity, with a notable decline in stock price and net outflow of funds, suggesting potential investor concerns [2]. Trading Activity - On September 25, a block trade occurred involving 101,000 shares of Chahua Co., with a transaction value of 2.5442 million yuan and a trading price of 25.19 yuan per share [2]. - Over the past three months, Chahua Co. has recorded a total of 7 block trades, amounting to 102 million yuan [2]. Stock Performance - The closing price of Chahua Co. on the same day was 25.19 yuan, reflecting a decrease of 6.57% [2]. - The stock's turnover rate was 4.50%, with a total trading volume of 280 million yuan for the day [2]. - There was a net outflow of 41.2566 million yuan in main funds, and the stock has seen a cumulative decline of 7.08% over the past five days, with total fund outflow of 43.4257 million yuan [2]. Company Background - Chahua Modern Household Products Co., Ltd. was established on March 3, 1997, with a registered capital of 24.182 million yuan [2].

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. and its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. have received drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution from the National Medical Products Administration of China [1][4]. Group 1: Drug Registration Details - Oseltamivir Phosphate Dry Suspension is approved for the treatment of influenza A and B in adults and children aged 2 weeks and older, and for prevention in individuals aged 1 year and older [2][3]. - The drug is classified as a Class 3 chemical drug and has been included in the National Basic Medical Insurance and Essential Drug List [2][3]. - The company has invested a total of RMB 13.41 million in the research and development of Oseltamivir Phosphate Dry Suspension [3]. Group 2: Lactulose Oral Solution - Lactulose Oral Solution is approved for the treatment of chronic functional constipation and is classified as a Class 4 chemical drug [4][5]. - The product has also been included in the National Basic Medical Drug Directory [6]. - The company has invested a total of RMB 3.31 million in the research and development of Lactulose Oral Solution [7]. Group 3: Clinical Trial Approval - The company has received approval for clinical trials of Pediatric Lung Heat Cough and Asthma Granules, which will be tested for use in treating influenza in children [11]. - This clinical trial is based on an existing product and aims to enhance its therapeutic indications [11]. - Further regulatory approvals are required before the product can be marketed [11].

Core Viewpoint - ST HULUWA (605199) and its wholly-owned subsidiary Guangxi Weiwei have received drug registration certificates from the National Medical Products Administration for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution [1] Group 1 - The company has obtained approval for the clinical trial of Pediatric Lung Heat Cough and Asthma Granules from the National Medical Products Administration [1]

Group 1 - ST HuLuWa announced the approval of drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution by the National Medical Products Administration [1] - The company's revenue composition for the year 2024 is projected to be 100% from the pharmaceutical manufacturing industry [1] - As of the report, ST HuLuWa has a market capitalization of 3.7 billion yuan [1] Group 2 - The announcement highlights a significant breakthrough in drug development, recognized by both Chinese and American authorities for its therapeutic efficacy [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）及全资子公司广西维威 制药有限公司（以下简称"广西维威"）近日分别收到国家药品监督管理局（以下简 称"国家药监局"）核准签发的关于磷酸奥司他韦干混悬剂、乳果糖口服溶液的《药 品注册证书》。现将有关情况公告如下： 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-067 海南葫芦娃药业集团股份有限公司 关于公司及全资子公司获得药品注册证书的公告 一、磷酸奥司他韦干混悬剂 （一）药品基本情况 药物名称：磷酸奥司他韦干混悬剂 剂型：干混悬剂 注册分类：化学药品 3 类 规格：0.36g（按 C₁₆H₂₈N₂O₄计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2303053 药品批准文号：国药准字 H20255455 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 （二）药品研发及相关 磷酸奥司他韦干混悬剂的适应症为：1．用于 ...

Group 1 - ST HuLuWa (605199.SH) announced the approval of drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution by the National Medical Products Administration [1] - Oseltamivir Phosphate Dry Suspension is indicated for the treatment of influenza A and B in adults and children aged 2 weeks and older, with a recommendation to use within 48 hours of symptom onset [1] - Lactulose Oral Solution is indicated for chronic functional constipation [1]